-
Functional control of myosin motors in the cardiac cycle Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-19 Malcolm Irving
-
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-19 Paul D. Morris, Ryan A. Anderton, Karina Marshall-Goebel, Joseph K. Britton, Stuart M. C. Lee, Nicolas P. Smith, Frans N. van de Vosse, Karen M. Ong, Tom A. Newman, Daniel J. Taylor, Tim Chico, Julian P. Gunn, Andrew J. Narracott, D. Rod Hose, Ian Halliday
-
Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives Eur. Heart J. (IF 37.6) Pub Date : 2024-07-19 Ulf Landmesser, Carsten Skurk, Apostolos Tzikas, Volkmar Falk, Vivek Y Reddy, Stephan Windecker
Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism
-
Genetic testing in early-onset atrial fibrillation Eur. Heart J. (IF 37.6) Pub Date : 2024-07-19 Shinwan Kany, Sean J Jurgens, Joel T Rämö, Ingrid E Christophersen, Michiel Rienstra, Mina K Chung, Morten S Olesen, Michael J Ackerman, Elizabeth M McNally, Christopher Semsarian, Renate B Schnabel, Arthur A M Wilde, Emelia J Benjamin, Heidi L Rehm, Paulus Kirchhof, Connie R Bezzina, Dan M Roden, M Benjamin Shoemaker, Patrick T Ellinor
Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed
-
Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-19 Tafadzwa T J Kufazvinei, Jason Chai, Katherine A Boden, Keith M Channon, Robin P Choudhury
After myocardial infarction (MI), patients with type 2 diabetes have an increased rate of adverse outcomes, compared to patients without. Diabetes confers a 1.5–2-fold increase in early mortality and, importantly, this discrepancy has been consistent over recent decades, despite advances in treatment and overall survival. Certain assumptions have emerged to explain this increased risk, such as differences
-
CircARCN1 aggravates atherosclerosis by regulating HuR-mediated USP31 mRNA in macrophages Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-18 Zhicheng Pan, Jialan Lv, Liding Zhao, Kaidi Xing, Runze Ye, Yuesheng Zhang, Siyuan Chen, Peng Yang, Hailong Yu, Yangkai Lin, Ruobing Li, Dongfei Wang, Juan Fang, Yang Dong, Jianpeng Sheng, Xiaolin Wang, Ge Shan, Shan Zhang, Hongqiang Cheng, Qingbo Xu, Xiaogang Guo
Aims Circular RNAs (circRNAs) are considered important regulators of biological processes, but their impact on atherosclerosis development, a key factor in coronary artery disease (CAD), has not been fully elucidated. We aimed to investigate their potential use in patients with CAD and the pathogenesis of atherosclerosis. Methods and Results Patients with stable angina (SA) or acute coronary syndrome
-
Extra-domain A containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-18 Isabell Singerer, Laura Tempel, Katja Gruen, Judith Heiß, Clara Gutte, Mattia Matasci, Andrea Schrepper, Reinhard Bauer, Alexander Berndt, Christian Jung, P Christian Schulze, Dario Neri, Marcus Franz
Aims Pulmonary vascular and right ventricular remodelling processes are important for development and progression of pulmonary hypertension (PH). The current study analyzed the functional role of the extra domain A containing fibronectin (ED-A+ Fn) for the development of PH by comparing ED-A+ Fn knockout (KO) and wild-type (WT) mice as well as the effects of an antibody-based therapeutical approach
-
Dietary patterns to promote cardiometabolic health Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-17 Neha J. Pagidipati, Pam R. Taub, Robert J. Ostfeld, Carol F. Kirkpatrick
-
Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score Eur. Heart J. (IF 37.6) Pub Date : 2024-07-17 Mohamed Dafaalla, Francesco Costa, Evangelos Kontopantelis, Mario Araya, Tim Kinnaird, Antonio Micari, Haibo Jia, Gary S Mintz, Mamas A Mamas
Background and Aims This study assessed the impact of incorporating cancer as a predictor on performance of the PRECISE-DAPT score. Methods A nationally linked cohort of ST-elevation myocardial infarction patients between 1 January 2005 and 31 March 2019 was derived from the UK Myocardial Ischaemia National Audit Project and the UK Hospital Episode Statistics Admitted Patient Care registries. The primary
-
Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-17 Benoit J. Arsenault, Krithika Loganath, Arnaud Girard, Simona Botezatu, Kang H. Zheng, Evangelos Tzolos, Kathia Abdoun, Lionel Tastet, Romain Capoulade, Nancy Côté, Neil Craig, Kwan L. Chan, James W. Tam, Koon K. Teo, Christian Couture, Marie-Annick Clavel, Patrick Mathieu, Sébastien Thériault, Erik S. G. Stroes, David E. Newby, Sotirios Tsimikas, Philippe Pibarot, Marc R. Dweck
ImportanceThere are currently no pharmacological treatments available to slow hemodynamic progression of aortic stenosis. Plasma lipoprotein(a) concentrations predict incident aortic stenosis but its association with hemodynamic progression is controversial.ObjectiveTo determine the association between plasma lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis
-
Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-17 Nick S. Nurmohamed, Emilie L. Gaillard, Shant Malkasian, Robin J. de Groot, Shirin Ibrahim, Michiel J. Bom, Yannick Kaiser, James P. Earls, James K. Min, Jeffrey Kroon, R. Nils Planken, Ibrahim Danad, Alexander R. van Rosendael, Andrew D. Choi, Erik S.G. Stroes, Paul Knaapen
ImportanceLipoprotein(a) (Lp[a]) is a causal risk factor for cardiovascular disease; however, long-term effects on coronary atherosclerotic plaque phenotype, high-risk plaque formation, and pericoronary adipose tissue inflammation remain unknown.ObjectiveTo investigate the association of Lp(a) levels with long-term coronary artery plaque progression, high-risk plaque, and pericoronary adipose tissue
-
Cardiac involvement in Chagas disease and African trypanosomiasis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-15 Ester Cerdeira Sabino, Maria Carmo P. Nunes, Johannes Blum, Israel Molina, Antonio Luiz P. Ribeiro
-
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers Eur. Heart J. (IF 37.6) Pub Date : 2024-07-16 Richard T Carrick, Alessio Gasperetti, Alexandros Protonotarios, Brittney Murray, Mikael Laredo, Iris van der Schaaf, Dennis Dooijes, Petros Syrris, Douglas Cannie, Crystal Tichnell, Nisha A Gilotra, Chiara Cappelletto, Kristen Medo, Ardan M Saguner, Firat Duru, Robyn J Hylind, Dominic J Abrams, Neal K Lakdawala, Julia Cadrin-Tourigny, Mattia Targetti, Iacopo Olivotto, Maddalena Graziosi, Moniek Cox
Background and Aims Pathogenic desmoplakin (DSP) gene variants are associated with the development of a distinct form of arrhythmogenic cardiomyopathy known as DSP cardiomyopathy. Patients harbouring these variants are at high risk for sustained ventricular arrhythmia (VA), but existing tools for individualized arrhythmic risk assessment have proven unreliable in this population. Methods Patients from
-
Beneficial normalization of cardiac repolarization by carnitine in transgenic SQT1 rabbit models Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-16 Ilona Bodi, Lea Mettke, Konstantin Michaelides, Tibor Hornyik, Stefan Meier, Saranda Nimani, Stefanie Perez-Feliz, Ibrahim el-Battrawy, Heiko Bugger, Manfred Zehender, Michael Brunner, Jordi Heijman, Katja E Odening
Aims Short-QT-syndrome type 1 (SQT1) is a genetic channelopathy caused by gain-of-function variants in HERG underlying the rapid delayed-rectifier K+ current (IKr), leading to QT-shortening, ventricular arrhythmias, and sudden cardiac death. Data on efficient pharmaco-therapy for SQT1 are scarce. In patients with primary carnitine-deficiency, acquired-SQTS has been observed and rescued by carnitine-supplementation
-
Genetic deletion or pharmacologic inhibition of HDAC6 protects the heart against ischemia/reperfusion injury by limiting TNFα-induced mitochondrial injury in experimental diabetes Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-13 Shelley L Baumgardt, Juan Fang, Xuebin Fu, Yanan Liu, Zhengyuan Xia, Ming Zhao, Ling Chen, Rachana Mishra, Muthukumar Gunasekaran, Progyaparamita Saha, Joseph M Forbess, Zeljko J Bosnjak, Amadou KS Camara, Judy R Kersten, Edward B Thorp, Sunjay Kaushal, Zhi-Dong Ge
Aims The histone deacetylase 6 (HDAC6) inhibitor, tubastatin A, reduces myocardial ischemia/reperfusion injury (MIRI) in type 1 diabetic rats. It remains unclear whether HDAC6 regulates MIRI in type 2 diabetic animals. Diabetes augments activity of HDAC6 and generation of tumor necrosis factor α (TNFα) and impairs mitochondrial complex I (mCI). Here we examined how HDAC6 regulates TNFα production,
-
Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study Eur. Heart J. (IF 37.6) Pub Date : 2024-07-12 You-Jung Choi, Jaehyun Lim, Sungho Bea, Jieun Lee, Jah Yeon Choi, Seung Young Rho, Dae-In Lee, Jin Oh Na, Hyung-Kwan Kim
Background and Aims Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. Methods This was a modified
-
Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature Eur. Heart J. (IF 37.6) Pub Date : 2024-07-12 Oskari Repo, Markus Juonala, Harri Niinikoski, Suvi Rovio, Juha Mykkänen, Hanna Lagström, Carol Y Cheung, Dawei Yang, Hanna Vaahtoranta-Lehtonen, Antti Jula, Jaakko Nevalainen, Tapani Rönnemaa, Jorma Viikari, Olli Raitakari, Robyn Tapp, Katja Pahkala
Background and Aims Retinal microvasculature characteristics predict cardiovascular morbidity and mortality. This study investigated associations of lifelong cardiovascular risk factors and effects of dietary intervention on retinal microvasculature in young adulthood. Methods The cohort is derived from the longitudinal Special Turku Coronary Risk Factor Intervention Project study. The Special Turku
-
Consequences of ionizing radiation exposure to the cardiovascular system Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-10 James W. S. Jahng, Mark P. Little, Hyunsoo J. No, Billy W. Loo, Joseph C. Wu
-
Coronary artery disease management in older adults: revascularization and exercise training Eur. Heart J. (IF 37.6) Pub Date : 2024-07-10 Rita Pavasini, Simone Biscaglia, Vijay Kunadian, Abdul Hakeem, Gianluca Campo
The mean age of patients with coronary artery disease (CAD) is steadily increasing. In older patients, there is a tendency to underutilize invasive approach, coronary revascularization, up-to-date pharmacological therapies, and secondary prevention strategies, including cardiac rehabilitation. Older adults with CAD commonly exhibit atypical symptoms, multi-vessel disease involvement, complex coronary
-
Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice Eur. Heart J. (IF 37.6) Pub Date : 2024-07-10 Luis R Lopes, Carolyn Y Ho, Perry M Elliott
Pathogenic variation in genes encoding proteins of the cardiac sarcomere is responsible for 30%–40% of cases of hypertrophic cardiomyopathy. The main clinical utility of genetic testing is to provide diagnostic confirmation and facilitation of family screening. It also assists in the detection of aetiologies, which require distinct monitoring and treatment approaches. Other clinical applications, including
-
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-10 André Zimerman, Eugene Braunwald, Jan Steffel, Nicolas M. Van Mieghem, Michael G. Palazzolo, Sabina A. Murphy, Cathy Zi Li Chen, Martin Unverdorben, Christian T. Ruff, Elliott M. Antman, Robert P. Giugliano
ImportanceIn older patients with atrial fibrillation who take anticoagulants for stroke prevention, bleeding is increased compared with younger patients, thus, clinicians frequently prescribe lower than recommended doses in older patients despite limited randomized data.ObjectiveTo evaluate ischemic and bleeding outcomes in patients 80 years and older with atrial fibrillation receiving edoxaban, 60
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-10 Catherine P. Benziger, Amanda Stebbins, Lisa M. Wruck, Mark B. Effron, Guillaume Marquis-Gravel, Peter M. Farrehi, Saket Girotra, Kamal Gupta, Sunil Kripalani, Daniel Munoz, Tamar S. Polonsky, Amber Sharlow, Jeffrey Whittle, Robert A. Harrington, Russell L. Rothman, Adrian F. Hernandez, W. Schuyler Jones
ImportanceAtherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dosed daily at 81 mg or 325 mg in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical
-
Machine Learning in Hypertrophic Cardiomyopathy: Nonlinear Model From Clinical and CMR Features Predicting Cardiovascular Events JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-07-10 Kankan Zhao PhD, Yanjie Zhu PhD, Xiuyu Chen MD, Shujuan Yang MD, Weipeng Yan BS, Kai Yang MD, Yanyan Song MD, Chen Cui MD, Xi Xu PhD, Qingyong Zhu PhD, Zhuo-Xu Cui PhD, Gang Yin BS, Huaibin Cheng MD, Minjie Lu MD, Dong Liang PhD, Ke Shi MD, Lei Zhao MD, Hui Liu MD, Jiayin Zhang MD, Liang Chen MD, Sanjay K. Prasad MD, Shihua Zhao MD PhD, Hairong Zheng PhD
-
Artificial intelligence-enhanced patient evaluation: bridging art and science Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Evangelos K Oikonomou, Rohan Khera
The advent of digital health and artificial intelligence (AI) has promised to revolutionize clinical care, but real-world patient evaluation has yet to witness transformative changes. As history taking and physical examination continue to rely on long-established practices, a growing pipeline of AI-enhanced digital tools may soon augment the traditional clinical encounter into a data-driven process
-
Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Iulia Iatan, Leo E Akioyamen, Isabelle Ruel, Amanda Guerin, Lindsay Hales, Thais Coutinho, Liam R Brunham, Jacques Genest
Background and Aims Familial hypercholesterolaemia (FH) is a highly prevalent monogenic disorder characterized by elevated LDL cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease. Sex disparities in diagnosis, lipid-lowering therapy, and achieved lipid levels have emerged worldwide, resulting in barriers to care in FH. A systematic review was performed to investigate sex-related
-
Lumican promotes calcific aortic valve disease through H3 histone lactylation Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Yuming Huang, Chunli Wang, Tingwen Zhou, Fei Xie, Zongtao Liu, Haiying Xu, Ming Liu, Shunshun Wang, Lanqing Li, Qingjia Chi, Jiawei Shi, Nianguo Dong, Kang Xu
Background and Aims Valve interstitial cells (VICs) undergo a transition to intermediate state cells before ultimately transforming into the osteogenic cell population, which is a pivotal cellular process in calcific aortic valve disease (CAVD). Herein, this study successfully delineated the stages of VIC osteogenic transformation and elucidated a novel key regulatory role of lumican (LUM) in this
-
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-06 Umidakhon Makhmudova, Elisabeth Steinhagen-Thiessen, Massimo Volpe, Ulf Landmesser
Nucleic acid-based therapies are being rapidly developed for prevention and management of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the delivery, safety, and effectiveness of these therapeutics in the past decade. These therapies can also modulate therapeutic targets that cannot be sufficiently addressed using traditional drugs or antibodies. Among the nucleic acid-targeted
-
The LDL cumulative exposure hypothesis: evidence and practical applications Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-05 Brian A. Ference, Eugene Braunwald, Alberico L. Catapano
-
Incidental Complication From a Left Atrial Appendage Device JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-03 Rimmy Garg, Sudhir Mungee, Rebecca Baumann
This case report describes a diagnosis of extracardiac mural thrombus and pulmonary emboli resulting from a left atrial appendage device in a patient with atrial fibrillation.
-
Large-Scale Proteomics in Early Pregnancy and Hypertensive Disorders of Pregnancy JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-03 Philip Greenland, Mark R. Segal, Rebecca B. McNeil, Corette B. Parker, Victoria L. Pemberton, William A. Grobman, Robert M. Silver, Hyagriv N. Simhan, George R. Saade, Peter Ganz, Priya Mehta, Janet M. Catov, C. Noel Bairey Merz, Jasmina Varagic, Sadiya S. Khan, Samuel Parry, Uma M. Reddy, Brian M. Mercer, Ronald J. Wapner, David M. Haas
ImportanceThere is no consensus regarding the best method for prediction of hypertensive disorders of pregnancy (HDP), including gestational hypertension and preeclampsia.ObjectiveTo determine predictive ability in early pregnancy of large-scale proteomics for prediction of HDP.Design, Setting, and ParticipantsThis was a nested case-control study, conducted in 2022 to 2023, using clinical data and
-
Chronic Total Occlusions Under the Microscope JACC Cardiovasc. Inte. (IF 11.7) Pub Date : 2024-07-03 Carlo Di Mario MD, Giulia Nardi MD
-
Optimizing the Use of Artificial Intelligence in Cardiology in 2024 JACC Cardiovasc. Inte. (IF 11.7) Pub Date : 2024-07-03 Stephen G. Ellis MD, Michael W. Kattan PhD
-
Mechanisms of Medial Wall Thinning in Chronic Total Occlusion JACC Cardiovasc. Inte. (IF 11.7) Pub Date : 2024-07-03 Takao Konishi MD, Rika Kawakami MD, Aimee E. Vozenilek PhD, Saikat Kumar B. Ghosh PhD, Weili Xu MD, Alyssa Grogan PhD, Palak Shah PhD, Takamasa Tanaka MD, Teruo Sekimoto MD, Tatsuya Shiraki MD, Kenji Kawai MD, Yu Sato MD, Masayuki Mori MD, Atsushi Sakamoto MD, Hideki Hisadome MD, Kazuhiro Ashida MD, Arielle Bellissard MD, Desiree Williams BA, Dilyan Dryanovski PhD, Robert Kutys MS, Qi Cheng MD, Maria
-
Predicting Successful Chronic Total Occlusion Crossing With Primary Antegrade Wiring Using Machine Learning JACC Cardiovasc. Inte. (IF 11.7) Pub Date : 2024-07-03 Athanasios Rempakos MD, Michaella Alexandrou MD, Deniz Mutlu MD, Arun Kalyanasundaram MD, Luiz F. Ybarra MD PhD, Rodrigo Bagur MD PhD, James W. Choi MD, Paul Poommipanit MD, Jaikirshan J. Khatri MD, Laura Young MD, Rhian Davies DO MS, Stewart Benton MD, Sevket Gorgulu MD, Farouc A. Jaffer MD PhD, Raj Chandwaney MD, Wissam Jaber MD, Stephane Rinfret MD, William Nicholson MD, Lorenzo Azzalini MD PhD
-
Atrial fibrillation burden: a new outcome predictor and therapeutic target Eur. Heart J. (IF 37.6) Pub Date : 2024-07-02 Nina Becher, Andreas Metzner, Tobias Toennis, Paulus Kirchhof, Renate B Schnabel
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden
-
Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis Eur. Heart J. (IF 37.6) Pub Date : 2024-07-02 Ziang Li, Sijing Cheng, Bo Guo, Lu Ding, Yu Liang, Yinghan Shen, Jinyue Li, Yiqing Hu, Tianxin Long, Xinli Guo, Junbo Ge, Runlin Gao, Philippe Pibarot, Bin Zhang, Haiyan Xu, Marie-Annick Clavel, Yongjian Wu
Background and Aims Physical activity has proven effective in preventing atherosclerotic cardiovascular disease, but its role in preventing degenerative valvular heart disease (VHD) remains uncertain. This study aimed to explore the dose–response association between moderate to vigorous physical activity (MVPA) volume and the risk of degenerative VHD among middle-aged adults. Methods A full week of
-
AI for Cardiac Function Assessment: Automation, Intelligence, and the Knowledge Gaps JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-07-01 Partho P. Sengupta MD DM, Y. Chandrashekhar MD DM
-
Body Surface Area Calculation and its Impact on Indexed Echocardiographic Measurements JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-07-01 Haoyi Zheng MD PhD
-
Reply: Body Surface Area Calculation and Its Impact on Indexed Echocardiographic Measurements JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-07-01 Torfinn Eriksen-Volnes MD, Havard Dalen MD PhD
-
Reply: The Influence of Outcome Prevalence on the Predictive Value of Coronary Plaque Characteristics JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-07-01 Guglielmo Gallone MD, Marco Gatti MD, Fabrizio d’Ascenzo MD, Gaetano Maria de Ferrari MD
-
The Influence of Outcome Prevalence on the Predictive Value of Coronary Plaque Characteristics JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-07-01 Ahmed Sayed MBBS, Keaton Wieschhaus MD, Sneha Sharma DO, Mouaz Al-Mallah MD, Daniel Addison MD
-
Private Equity in Cardiovascular Practice: Solution or Symptom? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-30 Edward T.A. Fry MD
-
Private Equity Acquisitions of Outpatient Cardiology Practices in the United States, 2013-2023 J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-30 Victoria L. Bartlett MD, Michael Liu MPhil, Shylie Ati BA, Robert W. Yeh MD MSc, Zhaonian Zheng MSc, Rishi K. Wadhera MD MPP MPhil
-
Transcatheter treatment of pure aortic regurgitation Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-27 Marco Barbanti, Giulia Laterra, Francesco Maisano
-
Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies—a review Eur. Heart J. (IF 37.6) Pub Date : 2024-06-28 Lauranne Scheldeman, Peter Sinnaeve, Gregory W Albers, Robin Lemmens, Frans Van de Werf
Acute ST-elevation myocardial infarction (STEMI) and acute ischaemic stroke (AIS) share a number of similarities. However, important differences in pathophysiology demand a disease-tailored approach. In both conditions, fast treatment plays a crucial role as ischaemia and eventually infarction develop rapidly. Furthermore, in both fields, the introduction of fibrinolytic treatments historically preceded
-
Autoimmune diseases and atherosclerotic cardiovascular disease Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-27 Florentina Porsch, Christoph J. Binder
-
Global epidemiology of heart failure Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-26 Muhammad Shahzeb Khan, Izza Shahid, Ahmed Bennis, Amina Rakisheva, Marco Metra, Javed Butler
-
Pulsed-field ablation: a revolution in atrial fibrillation therapy Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-25 Leonid Maizels, Jonathan M. Kalman
The advent of pulsed-field ablation — a series of ultra-rapid, high-energy pulses that result in non-thermal cell death via electroporation — is revolutionizing the field of atrial fibrillation ablation. Data on first iterations of the technology indicate that safety and efficacy are at least similar to that of thermal ablation but with meaningfully shorter procedure duration.
-
Management of cardiac sarcoidosis Eur. Heart J. (IF 37.6) Pub Date : 2024-06-26 Rakesh Sharma, Vasileios Kouranos, Leslie T Cooper, Marco Metra, Arsen Ristic, Bettina Heidecker, John Baksi, Eleanor Wicks, Jose L Merino, Karin Klingel, Massimo Imazio, Christian de Chillou, Carsten Tschöpe, Petr Kuchynka, Steffen E Petersen, Theresa McDonagh, Thomas Lüscher, Gerasimos Filippatos
Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a
-
Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome JAMA Cardiol. (IF 14.8) Pub Date : 2024-06-26 Jinho Lee, Do-Yoon Kang, Hoyun Kim, Yeonwoo Choi, Sangyong Jo, Jung-Min Ahn, Seonok Kim, Yong-Hoon Yoon, Seung-Ho Hur, Cheol Hyun Lee, Won-Jang Kim, Se Hun Kang, Chul Soo Park, Bong-Ki Lee, Jung-Won Suh, Jae Woong Choi, Kee-Sik Kim, Su Nam Lee, Seung-Jung Park, Duk-Woo Park
ImportanceThe appropriate follow-up surveillance strategy for patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI) remains unknown.ObjectiveTo assess clinical outcomes in patients with and without ACS who have undergone high-risk PCI according to a follow-up strategy of routine stress testing at 12 months after PCI vs standard care alone.Design, Setting
-
Reappraisal of the Concept and Implications of Pulmonary Hypertension in Degenerative Mitral Regurgitation JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-06-26 Benjamin Essayagh MD, Giovanni Benfari MD, Clemence Antoine MD, Francesco Grigioni MD PhD, Thierry Le Tourneau MD PhD, Jean-Christian Roussel MD PhD, Jeroen J. Bax MD PhD, Nina Ajmone Marsan MD PhD, Steele C. Butcher MD MPhil, Christophe Tribouilloy MD PhD, Dan Rusinaru MD PhD, Aviram Hochstadt MD MPH, Yan Topilsky MD, Edward El-Am MD, Prabin Thapa MSc, Hector I. Michelena MD, Maurice Enriquez-Sarano
-
Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway Eur. Heart J. (IF 37.6) Pub Date : 2024-06-25 Mayra Vera-Aviles, Syeeda Nashitha Kabir, Akshay Shah, Paolo Polzella, Dillon Yee Lim, Poppy Buckley, Charlotte Ball, Dorine Swinkels, Hanke Matlung, Colin Blans, Philip Holdship, Jeremy Nugent, Edward Anderson, Michael Desborough, Stefan Piechnik, Vanessa Ferreira, Samira Lakhal-Littleton
Background and Aims Intravenous iron therapies contain iron–carbohydrate complexes, designed to ensure iron becomes bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other tissues obtain and handle this iron remains unknown. This study addresses this question in the context of the heart. Methods A prospective observational study was conducted in 12 patients
-
Forward programming of hiPSCs via the transcription factor ETV2: rapid, reproducible, and cost-effective generation of highly enriched, functional endothelial cells Cardiovasc. Res. (IF 10.2) Pub Date : 2024-06-25 Sarah Rieck, Kritika Sharma, Carlotta Altringer, Michael Hesse, Christos Triantafyllou, Yanhui Zhang, Volker Busskamp, Bernd K Fleischmann
Aims Endothelial cell (EC) dysfunction plays a key role in the initiation and progression of cardiovascular disease. However, studying these disorders in ECs from patients is challenging, hence the use of human induced pluripotent stem cells (hiPSCs) and their in vitro differentiation into ECs represents a very promising approach. Still, the generation of hiPSC-derived ECs (hECs) remains demanding
-
-
The FDA and the Cardiovascular Community J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Haider J. Warraich MD, Robert M. Califf MD
-
The Editorship of the Journal of the American College of Cardiology: Passing the Torch J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Eugene Braunwald MD
-
Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Eldad Ben-Chetrit MD, Mark Nidorf MD, Rodney Falk MD, Paul M Ridker MD
-
Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Rohan Khera MD MS, Evangelos K. Oikonomou MD DPhil, Girish N. Nadkarni MD MPH, Jessica R. Morley PhD, Jenna Wiens PhD, Atul J. Butte MD PhD, Eric J. Topol MD
-
Lessons for Cardiovascular Clinical Investigators: The Tumultuous 2,500-Year Journey of Physicians Who Ignited Our Fire J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Milton Packer MD
-
Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP Into a Paradigm of Integrated Care J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-23 John W. Ostrominski MD, Anuradha Lala MD